Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RO7296682 + atezolizumab
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**RO7296682 + atezolizumab** is an experimental combination therapy for cancer. RO7296682 (also known as RG6292 or vopikitug) is an afucosylated, human IgG1 monoclonal antibody targeting CD25 (the IL-2 receptor alpha chain) designed to deplete regulatory T cells (Tregs) selectively within the tumor microenvironment, sparing effector T cells, and potentially enhancing anti-tumor immune response. Atezolizumab (Tecentriq) is a monoclonal antibody that inhibits programmed death-ligand 1 (PD-L1), blocking its interaction with PD-1 and B7.1 receptors, which results in the activation of T cells and restoration of anti-cancer immune activity. The combination is being investigated for its safety, tolerability, and anti-tumor activity in advanced and metastatic solid tumors. Clinical studies are sponsored by Hoffmann-La Roche.[1][3][5][7]
- Brand names
- Tecentriq
- Other names
- vopikitug
02
Targets
IL2RA (Interleukin-2 receptor alpha subunit)CD274 (Programmed cell death protein 1 ligand 1)FcγRIIIa (Low affinity immunoglobulin gamma Fc region receptor III-A)
Beyond the preview
Go deeper on RO7296682 + atezolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RO7296682 + atezolizumab.